Dr. Adriele Prina Mello

Adriele Prina-Mello, PhD, is an Ussher Assistant Professor in Translational Nanomedicine, Department of Clinical Medicine at the Trinity Translational Medicine Institute, School of Medicine. AMBER centre Investigator, CRANN Principal Investigator at Trinity College, Dublin. Chair of the working group in Characterization and Toxicology at the European Technology Platform for Nanomedicine. Expert Member of Nanosafety cluster, the EC Task Force in Characterization and European Materials Characterisation Council. Founder and Director of the Laboratory for Biological Characterization of Advanced Materials, the Irish-branch of the European Nanomedicine Characterization Laboratory (EU-NCL), the flagship infrastructure project funded by the European Commission, in partnership with the US-National Cancer Institute Nano Characterization Laboratory)for enabling Translational Nanomedicine. My objective is to drive LBCAM to become a core nanomedicine enabling infrastructure for educational training (e.g., undergraduates, postgraduates) and international collaboration with academia, industry, clinicians and public bodies. Prina-Mello's research interests are focused on the translation of nanotechnology-enabled products (e.g., medical device, medicinal drugs, hybrid products such as theranostics); advanced materials and their multifunctional solutions; device and instrumentation applications into the medical research area as Nanomedicine tools with the potential to become next generation medical standards or standards of care. The key Nanomedicine areas of interest where I have developed expertise are: 1)Nanodiagnostics: advanced in vitro/ in vivo diagnostic and imaging devices and instrumentation. 2) Theranostics and Personalised Medicine: therapeutics based on nanotechnology and multilayered structures for localised and personalised medicine. 3) Regenerative Medicine: biomedical devices and nanotechnology and nanomaterials applied to tissue engineering. 4) Nanocharacterization and Safety: safe-by-design, responsible innovation development and regulatory compliance. Credited with more than 70 peer-review publications, 6 book chapters, 2 Booklets (as editor), 2 Special Issue (as topic editor), 7 invited scientific reviews, > 25 invited lectures, >50 conference proceedings, >100 posters. (all indexed in Google Scholars, Research Gate, or RSS, April 2016) Contributed to educational and learning by lecturing undergraduate students in Medicine and postgraduate Master degrees in Molecular Medicine, Translational Oncology, Pharmaceutical Science. Since 2010 provided mentoring, educational training, and transferable skills to more than 15 students who are now accomplished professionals. Prina-Mello's scientific and teaching international collaborators are the results of the extensive European Commission involvement and research projects activity. Prina-Mello is an active member at TCD of the following: Trinity Cancer committee, AMBER/CRANN Environmental, Health, and Safety (EHS) platform, the TTMI TARGET Radiobiology group, the TTMI outreach committee, the TTMI Health and Safety, the Translational Child Health and Paediatrics forum, the St. James's Intensive Care Unit research group.

  Bioelectromagnetism   Bioengineering   Biomagnetism   Biomaterials   Biomechanics   Biomechanics, Biomedical Engineering   Biomedical Engineering   Biomedical sciences   Biophysics   Bioreactors   Biosensors   Biotechnology   Cell and tissue development   Cell Communication   Cytoskelton, cell division   Intra and intercellular signalling   Mechanical Engineering   Medical Devices Engineering   Microelectronics technology   Multisensory technology, multi sensing   Nano Biotechnology   Nanochemistry   Nano-Materials   NanoMedicine   Nanotechnology   Neurobiology   Stem Cell biology and hematopoiesis   Surface and interface physics   Tissue Culture

Prina-Mello's research interests are focused on: 1) Advanced Translational Research of NanoMedicine (from Pre-clinical to Clinical, Precision, Personalised, Targeted nanomedicine), 2) Therapeutics based on nanotechnology and multilayered structures, 3) Theranostics and Personalised Medicine (in vitro/ in vivo diagnostic, imaging and treatment), 4) Dynamic interaction between nano-developed-products and biologically relevant models (nanotoxicology, nanobiocompatibility, nanosafety and nanobiotechnology), 5) Microfluidic systems applied to ultra-sensitive diagnostics (lab-on-a chip) 6) Biomedical devices and Tissue engineering applications of nanotechnology and nanomaterials, 7) Nanomedicine Characterization and Safety 8) In vitro complex models and tissue mimetic 9) Compliance to 3Rs principle 10) Development of Regulatory Science and Policy for nanotechnology-enabled medicine. Additional interests are also in pre-clinical screening, interdisciplinary science and research for nanomedicine and nanotechnology-based medical technology development (e.g., biomaterials, biocompatibility, high throughput and content screening, multiparametric analysys, data mining, bioelectromagnetisms biophysics, biomechanics, single cell assay and cellular engineering).